

Axinn Obtains Fourth Circuit Victory in Generic Celebrex[®] Case

A decorative graphic on the right side of the header, featuring a light blue and white wavy line that curves upwards, set against a background of a grey grid pattern.

NEWS | 1 MIN READ

December 17, 2014

At the U.S. Court of Appeals for the Fourth Circuit, Axinn obtained a victory that will help its client, Watson Laboratories (now Actavis), speed its generic version of Celebrex[®] to market.

An earlier lower court decision had effectively barred Watson Laboratories and others from bringing their drugs to market until June 2015.

Watson and Mylan Pharmaceuticals initially sued FDA in federal court, challenging an Agency letter decision that concluded that the companies were not eligible for a period of 180-day marketing exclusivity on the launch of their generic versions of Celebrex[®] because a reissued patent, according to FDA, was part of the same “bundle of rights” as an original patent. The U.S. District Court for the Northern District of West Virginia ruled in favor of the Agency, finding that the Agency’s interpretation of the statute regarding exclusivity periods was reasonable and was owed deference.

The Fourth Circuit Court of Appeals reversed and remanded the case, finding in favor of Axinn’s client and holding that FDA’s interpretation was contrary to the unambiguous statute.

Related People



Mark D. Alexander



Thomas K. Hedemann

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
MEDIA MENTIONS ANTITRUST

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved